RNA Virus Infections clinical trials at UC Health
1 research study open to eligible people
open to eligible people ages 18 years and up
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.
at UC Davis UC Irvine